Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC

INTRODUCTION: BRAF mutations (present in 2%–3% of NSCLC) are a known oncogenic driver and emerging therapeutic target. There is a scarcity of real-world data describing the clinical characteristics, treatment patterns, and effectiveness of targeted BRAF-inhibiting and immune checkpoint inhibitor (IC...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibson, Amanda J.W., Pabani, Aliyah, Dean, Michelle L., Martos, Guillermo, Cheung, Winson Y., Navani, Vishal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006852/
https://www.ncbi.nlm.nih.gov/pubmed/36915629
http://dx.doi.org/10.1016/j.jtocrr.2022.100460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006852/
https://www.ncbi.nlm.nih.gov/pubmed/36915629
http://dx.doi.org/10.1016/j.jtocrr.2022.100460

Ejemplares similares